Oscotec Inc.
Financials
Valuation Metrics
Oscotec Inc.'s Market Cap is ₩1.3T. At end of 2025 it was ₩1.7T. Ranked #261 of 2,436 in KR market (top 11%), #63 of 1,649 on KOSDAQ (top 4%), #30 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 13%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.32T KRW | KR#261/2,436 Sec#30/234 |
| Revenue | 101.55B KRW | KR#1,385/2,436 Sec#87/234 |
| Net Income | 57.17B KRW | KR#332/2,436 Sec#23/234 |
| Total Assets | 222.34B KRW | KR#1,214/2,436 Sec#88/234 |
| Net Assets | 182.53B KRW | KR#978/2,436 Sec#69/234 |
| Employees | 51 | KR#2,022/2,436 Sec#183/234 |
| Value | ||
| P/E | 23.15x | KR#1,164/2,436 Sec#68/234 |
| P/B | 7.25x | KR#2,301/2,436 Sec#197/234 |
| P/S | 13.04x | KR#2,300/2,436 Sec#169/234 |
| EV/EBITDA | 26.33x | KR#1,146/2,436 Sec#73/234 |
| Profitability | ||
| ROE | 31.32% | KR#43/2,436 Sec#3/234 |
| ROA | 25.71% | KR#16/2,436 Sec#2/234 |
| Op. Margin | 49.64% | KR#12/2,436 Sec#1/234 |
| Revenue Growth | 88.40% | KR#165/2,436 Sec#22/234 |
| Financial Health | ||
| Debt Ratio | 121.81% | KR#693/2,436 Sec#84/234 |
| Total Debt | 16.63B KRW | KR#1,428/2,436 Sec#121/234 |
| Cash | 13.13B KRW | KR#1,507/2,436 Sec#113/234 |
| Current Ratio | 5.37x | KR#267/2,436 Sec#52/234 |
| Net Debt/EBITDA | 0.07x | KR#695/2,436 Sec#43/234 |
| Performance | ||
| 1Y Return | 12.52% | KR#498/2,436 Sec#40/234 |
| 1M Return | -0.29% | KR#909/2,436 Sec#82/234 |
| From 52W High | -47.58% | KR#1,079/2,436 Sec#89/234 |
| 1Y MDD | -54.84% | KR#1,151/2,436 Sec#91/234 |
| Trading | ||
| Volume | 259,788 shares | KR#456/2,436 Sec#45/234 |
| Foreign Own. | 13.01% | KR#375/2,436 Sec#30/234 |
| Per Share | ||
| EPS | 1,452 KRW | KR#481/2,436 Sec#33/234 |
| BPS | 4,676 KRW | KR#1,493/2,436 Sec#109/234 |
Company Info
Oscotec, a new drug development biotechnology company established in 1998, specializes in synthetic new drug development, building a differentiated business model through the commercialization of its research products. Its targeted anticancer lung cancer treatment received approval as a first-line treatment from the Korean Ministry of Food and Drug Safety and the U.S. FDA. The company's autoimmune disease treatment has applied for additional clinical trials after completing global Phase 2a for ITP disease, while its next-generation anticancer drug received U.S. FDA Phase 1 Investigational New Drug (IND) approval, and its Alzheimer's disease treatment is undergoing Phase 1 clinical trials in the U.S. Oscotec is headquartered in Seongnam-si, Gyeonggi-do.